MedTrace Logo

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

NCT04917250 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-06-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients

Conditions

  • Extranodal NK/T-cell Lymphoma

Interventions

DRUG

Gemcitabine

1000mg/㎡，d1,4 ivdrip

DRUG

Pegaspargase

2500IU/㎡, maximum dose less than 3750IU

DRUG

Etoposide

100mg/㎡，d1-3 ivdrip

DRUG

Dexamethasone

20mg/d d1-4 ivdrip

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Principal Investigators

  • Liang Wang, M.D. · Beijing Tongren Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-20
Primary Completion
2021-06-30
Completion
2021-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04917250 on ClinicalTrials.gov